The aryl hydrocarbon receptor (AhR) mediates many of the biological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and transcriptional activation of genes encoding a number of xenobiotic metabolizing enzymes. Prenatal exposure of mice to TCDD causes severe alterations in embryo and fetal development, including hydronephrosis and cleft palate. However, the mechanisms underlying these effects are unclear. In this work, the teratogenicity of TCDD in AhR-null mice was evaluated to determine if this effect is mediated by the AhR. Homozygous wild-type (؉/؉) or AhR-null (؊/؊) female mice were mated with males of the same genotype overnight. On gestation day (GD)-10, mice were intubated orally with either corn oil (vehicle control) or 25 g/kg TCDD. Fetuses were examined on GD18 for visceral and skeletal alterations. For non-TCDD-exposed litters, all developmental endpoints were comparable between genotypes, with the exception of a lower incidence of large interfrontal bones in (؊/؊) mice. For TCDD-exposed litters, (؉/؉) fetuses had a significantly greater incidence of cleft palate, hydronephrosis, small kidneys, tortuous ureters and greater dilation of the renal pelves and ureters compared to (؊/؊) fetuses. Interestingly, an increased resorption rate was observed in (؊/؊) fetuses exposed to TCDD.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a prototypical aryl hydrocarbon, is ubiquitously present in the environment (Czuczwa and Hites, 1984) . Exposure to TCDD induces transcriptional activation of genes encoding xenobiotic metabolizing enzymes, including cytochromes P450 (CYP1A1, CYP1A2, CYP1B1), phase II enzymes such as UDP-glucuronyl-S-transferases and sulfotransferases, and other growth factors and proteins (Gonzalez et al., 1985; Kimura et al., 1986; Nebert, 1989; Rowlands and Gustafsson, 1997) . Changes in gene expression induced by TCDD and related chemicals are initiated after binding to the aryl hydrocarbon receptor (AhR), followed by dimerization with the aryl hydrocarbon receptor nuclear translocator and interaction of the complex with gene regulatory elements (Rowlands and Gustafsson, 1997; Whitlock, 1990) .
TCDD exposure can result in carcinogenesis, immunosuppression, and tissue and organ toxicity, as well as developmental toxicity and teratogenesis, when administered prenatally Nebert, 1989) . Alterations in gene expression that result from TCDD exposure are thought to contribute to the mechanisms underlying many of the effects induced by this compound. The AhR-null mouse was used to definitively show that TCDD-induced tissue/organ-specific toxicity and transcriptional activation of genes encoding xenobiotic metabolizing enzymes are mediated by the AhR (Fernandez-Salguero et al., 1995 . However, the precise role of the AhR in mediating the variety of effects induced by TCDD has not been established. For example, cleft palate and urinary tract defects, in particular hydronephrosis, are malformations commonly observed in fetuses from TCDD-exposed mice, yet whether or not these malformations occur as a direct effect of AhR-mediated alterations is unknown. Although the AhR mediates many of the changes in gene expression as a result of TCDD exposure, the putative target genes that cause developmental toxicity are currently unidentified.
While the AhR mediates many of the toxicological changes caused by TCDD through modulation of target gene expression, there is evidence that suggests that some alterations induced by TCDD may occur through mechanisms that do not involve the AhR. Using either inhibitors of AhR binding or cell lines that exhibit highly reduced levels of AhR, it has been shown that induction of lipid peroxidation or fos and jun mRNA expression in response to TCDD administration may not require the AhR (Ashida et al., 1996; Hoffer et al., 1996; Puga et al., 1992) . It is not known whether putative AhRindependent events contribute to the underlying mechanisms of TCDD toxicity or teratogenicity.
In addition to the possible role of the AhR in mediating TCDD-induced developmental toxicity, there is also evidence that the AhR is required during embryogenesis. Preimplantation mouse embryos express AhR mRNA from the eight-cell stage until the blastocyst stage of development, and exposure to antisense oligonucleotides inhibits differentiation and cell proliferation (Peters and Wiley, 1995) . This suggests that the AhR has a functional role during early embryonic development. Additional support for a developmental role for the AhR is the high incidence of neonatal mortality observed in offspring from AhR transgenic mice (Fernandez-Salguero et al., 1995) . However, there are viable offspring obtained from these matings, indicating that the receptor is not essential for embryo/fetal development. Further, two other AhR-null mouse lines have been generated and no difference in neonatal mortality in these mouse lines has been reported (Mimura et al., 1997; Schmidt et al., 1996) . This disparity could be due to a number of reasons, including differences in the timing of examination as well as to the different methods used to attenuate AhR expression (Table 1) . Thus, the role of AhR during development remains unclear.
Recently, evidence was provided suggesting that the AhR is not required for development and that the teratogenicity of TCDD is mediated by the AhR using an AhR-null mouse model (Mimura et al., 1997) . To further investigate the prenatal role of the AhR, fetal development in wild-type and AhRnull mice was assessed, using an AhR-null mouse developed at the National Institutes of Health (Fernandez-Salguero et al., 1995) . In addition, TCDD-induced teratogenicity was evaluated in wild-type and AhR-null mice to evaluate if this effect is mediated by the AhR in this mouse model.
METHODS
Homozygous wild-type (ϩ/ϩ) or AhR-null (Ϫ/Ϫ) mice were obtained from the F 4 generation (from sibling matings) of mixed background mice (C57BL/ 6N ϫ Sv/129) generated at the National Institutes of Health (FernandezSalguero et al., 1995) . Eight-to 12-week old female mice were housed in a temperature-and light-controlled environment (25°C, 12 h light and 12 h dark cycle). Female mice of either genotype were mated with males of the same genotype overnight, and GD0 was assigned as the morning after mating. Maternal body weight was recorded on GD0, GD10 and GD18. On GD10, mice were intubated orally with either corn oil (vehicle control; Mazola corn oil filtered through a 0.2 m membrane) or TCDD dissolved in corn oil (25 g TCDD/kg body weight). TCDD was purchased commercially with a minimum purity of 98% (AccuStandard, Inc., New Haven, CT). The stock solution for dosing was 5 g TCDD/mL and the dosing volume was 5 mL/kg maternal body weight. This dose of TCDD has been shown to cause a high frequency of hydronephrosis and cleft palate in C57BL/6N mice , a strain that is known to be particularly responsive to TCDD.
Mice were killed on GD18 by overexposure to carbon dioxide and gravid uterine weights were recorded. For each litter, the number of live fetuses, dead fetuses and resorption sites were counted. Live fetuses in each litter were individually weighed, fixed in 70% ethanol, and subsequently examined by dissection for thoracic and abdominal visceral defects. Scoring systems were used to evaluate the dilation of the renal pelves and ureters (1 ϭ normal, 4 ϭ severely dilated). The specimens were then cleared and stained with alizarin red S for skeletal examination. Skeletal evaluations included determination of the degree of ossification of the phalanges, metacarpals, metatarsals, vertebrae, sternabrae, and skull. The size of the anterior fontanel was scored (1 ϭ normal, 4 ϭ severely enlarged), as was ossification of the supraoccipital (1 ϭ well ossified, 4 ϭ completely unossified). The size of the interfrontal bone, a rostral ossification center between the frontal bones, was also scored (1 ϭ absent, 4 ϭ large). The absence of an intrafrontal bone is considered "normal;" however, in some mouse strains there is considerable variance associated with the presence or absence of this feature. The length of the lumbar ribs was classified as focal, short (less than one-half the length of the adjacent rib), or extra (at least one-half the length of the adjacent ribs).
For maternal data, individual dams were used as the experimental unit. For developmental data, the litter was used as the experimental unit. Findings were evaluated by analysis of variance (ANOVA) or covariance, using the general linear models (GLM) procedure in SAS (Cary, NC). Fetal weight was analyzed as litter means with the number of live fetuses as a covariate. Similarly, the number of implants was used as a covariate in the analysis of litter size. When significant treatment effect was detected by ANOVA, Student' t-test on least squares means (LSM) was used to compare (ϩ/ϩ) versus (Ϫ/Ϫ) groups receiving the same TCDD treatment. This experiment took place in 2 parts. In the first part, vehicle control-treated mice and litters were evaluated, and in the 
RESULTS
Maternal weight gain during pregnancy was similar between untreated (ϩ/ϩ) and (Ϫ/Ϫ) dams (Table 2 ). In contrast, maternal weight gain was significantly lower in (Ϫ/Ϫ) dams treated with TCDD compared to (ϩ/ϩ) dams treated with TCDD (Table 2) . However, extrauterine weight gain was comparable for all groups, indicating that reduced weight gain in the TCDD-treated (Ϫ/Ϫ) mice may have been due to developmental rather than maternal toxicity (Table 2) . No overt clinical signs of maternal toxicity were observed in any of the groups.
The number of implantation sites per uterus was similar between control (ϩ/ϩ) and (Ϫ/Ϫ) mice, as well as TCDDtreated (ϩ/ϩ) and (Ϫ/Ϫ) mice. Whereas the percentage of resorptions was comparable between control (ϩ/ϩ) and (Ϫ/Ϫ) mice, the percentage of resorptions in the TCDD-treated groups was significantly higher in (Ϫ/Ϫ) mice compared to (ϩ/ϩ) mice (Table 2) . Average fetal weight and crown-rump length were similar between genotypes for the control and TCDD-treated groups. However, the lack of statistical power due to the relatively low number of litters examined may have prevented identification of lower average fetal weight in the (Ϫ/Ϫ) fetuses treated with TCDD compared to similarly treated (ϩ/ϩ) fetuses. While the average number of fetuses per litter was lower in (Ϫ/Ϫ) mice treated with TCDD compared to TCDD-treated (ϩ/ϩ) mice when analyzed with ANOVA, using implantation sites as a covariance, this was not statistically significant (Table 2) .
Fetal examination of the control litters revealed only one finding of significant difference between genotypes. While interfrontal bones are typically not found in many strains of mice, in this mixed strain of mouse, a lower incidence of large (i.e., score ϭ 4) interfrontal bones was found in (Ϫ/Ϫ) fetuses (20% per litter) compared to (ϩ/ϩ) fetuses (36% per litter) (Table 3) . However, the incidences of interfrontal bones of any size were comparable in these groups (81% and 86%, respectively). For the TCDD-treated groups, there were higher dilation scores for the ureter and renal pelvis, as well as higher incidences of hydronephrosis (dilation score ϭ 4; 33% versus 0%), tortuous ureter (27% versus 0%), dilated renal pelvis (79% versus 9%), small kidney (21% versus 0%), and cleft palate (72% versus 9%) in the (ϩ/ϩ), compared to the (Ϫ/Ϫ) progeny (Table 3 ). There was no clear morphological distinction between genotypes for the clefts in the TCDD-exposed fetuses. In addition, ablepharia was found in the TCDD-treated (Ϫ/Ϫ) group (five fetuses, two litters); the increased incidence was marginally significant (p ϭ 0.08) compared to the TCDDtreated (ϩ/ϩ) group. Malformations observed sporadically included small thymus, small spleen, omphalocele, cleft lip, misshapen kidney and ventricular septal defect.
DISCUSSION
Earlier studies indicated that approximately 50% of (Ϫ/Ϫ) mouse pups from heterozygous (ϩ/Ϫ) matings died within 1-4 days postnatally (Fernandez-Salguero et al., 1995) . There is also evidence that early embryonic development requires the 14.8 Ϯ 5.8 27.5 Ϯ 9.6 15.9 Ϯ 3.9 43.5 Ϯ 7.0* Postimplantation loss (%) 16.0 Ϯ 5.9 27.5 Ϯ 9.6 15.9 Ϯ 3.9 46.2 Ϯ 6.9* Crown-rump length (mm) 22.3 Ϯ 0.3 22.5 Ϯ 0.2 21.6 Ϯ 1.1 21.6 Ϯ 0.6 Fetal weight (g) 1.15 Ϯ 0.04 1.26 Ϯ 0.04 1.14 Ϯ 0.13 1.03 Ϯ 0.07
Note. Pregnant (ϩ/ϩ) or (Ϫ/Ϫ) female mice were intubated orally with either corn oil (vehicle control) or TCDD (25 g/kg body weight) on GD10. Maternal and fetal endpoints were evaluated on GD18. Values represent the mean Ϯ SE.
* Significantly different from (ϩ/ϩ) group receiving same treatment (p Ͻ 0.05).
AhR for differentiation and/or cell proliferation (Peters and Wiley, 1995) . These observations suggest that the AhR may have an important role during development. The mechanism underlying this putative effect is unknown, but the increased neonatal mortality could be due to alterations in gene expression that occur during embryonic/fetal development. For this reason, in the present study, GD18 fetuses were carefully examined, and except for a lower incidence of large interfrontal bones, there were no apparent differences in any of the developmental endpoints analyzed in control (Ϫ/Ϫ) litters compared to control (ϩ/ϩ) litters. In particular, no difference was observed in the number of implantation sites, percentage of resorptions nor any other significant alteration in fetal development compared to (ϩ/ϩ) litters. This is consistent with other reports showing that two other AhR-null mouse lines do not exhibit increased neonatal mortality of (Ϫ/Ϫ) offspring (Mimura et al., 1997; Schmidt et al., 1996) . This suggests that development per se was grossly unaffected in the absence of AhR, or that other genes may have compensated in part for the loss of the AhR. Alternatively, while gross fetal morphology was generally unaffected in (Ϫ/Ϫ) litters, neonatal survival could have been compromised through functional deficits not assessed in this work. It should be pointed out that the (Ϫ/Ϫ) mice used in this study were from the F 4 generation from the original (ϩ/Ϫ) colony of mixed background mice that exhibited decreased postnatal survival. Thus, healthier mice might have been selected, resulting in a colony that is now more resistant to this trait. In support of this idea, the mean proportion of dead pups per litter within one week postnatally, is approximately 16 Ϯ 4% in AhR (Ϫ/Ϫ) pups derived from the original colony and currently in house at the U.S. EPA (unpublished observation). The only difference in fetal development noted between genotypes in the vehicle control-treated groups was a lower incidence of large interfrontal bones in the (Ϫ/Ϫ) fetuses. Although the biological significance of this finding is unclear, increased (Beck, 1981 (Beck, , 1983 ) and decreased incidences of this bone (Narotsky et al., 1994) have been previously reported as indicators of developmental toxicity. Additionally, the incidence of this bone varies among different mouse strains (Fukuta et al., 1988) and has been shown to be associated with gene mutations in the mouse (Johnson, 1976) .
More importantly, only minimal teratogenicity of TCDD was observed in (Ϫ/Ϫ) mice compared to TCDD-treated (ϩ/ϩ) mice which provides evidence that the AhR mediates TCDD-induced teratogenicity. This is consistent with a recent report demonstrating similar results in another AhR-null mouse line (Mimura et al., 1997) . Since AhR can modulate gene expression of TCDD-responsive genes, it is possible that TCDD teratogenicity is a result of altered gene expression during critical periods of development. The best characterized mechanisms that have been postulated to underlie TCDDinduced cleft palate and alterations in urinary tract development are changes in growth factor expression, with subsequent distortion of morphogenesis in specific cell populations in these tissues. Specifically, it was shown that TCDD causes decreases in TGF␣, TGF␤ and EGF expression in embryonic epithelial cells in developing palate and urinary tract (Abbott et al., 1987a,b; Birnbaum, 1989, 1990a,b; Bryant et al., 1997) . Whether the AhR regulates this effect, directly or indirectly, cannot be determined from this work, but further studies using this model system should help to conclusively identify putative target genes affected by TCDD during development. Although dioxin-responsive elements have been identified in promoter regions of growth factors (Lai et al., 1996) , and administration of TCDD causes alterations of mRNA levels for different growth factors (Gaido et al., 1992; Lai et al., 1997; Rowlands and Gustafsson, 1997) , the AhR has not been shown to directly control genes encoding growth factors. It is noteworthy that TGF␤3-null mice develop cleft palate that is histologically similar to that observed in offspring from normal mice treated prenatally with TCDD, suggesting that cleft palate formation may involve both AhR and TGF␤ signalling pathways (Kaartinen et al., 1995) . Additionally, the AhR can significantly affect retinoic acid metabolism (Andreola et al., 1997) which could influence numerous developmental processes underlying cellular differentiation. While it is possible that the increased incidence of resorptions in the TCDD-treated (Ϫ/Ϫ) mice may have at least partly masked the occurrences of palate and urinary tract defects, the extent of prenatal mortality was insufficient to fully account for the decreased incidences of these abnormalities. Thus, these data support the hypothesis that the AhR mediates the teratogenic effects of TCDD in mice.
The low incidence of cleft palate in the (Ϫ/Ϫ) fetuses from TCDD-treated mice also suggests that mechanisms which do not require the AhR may contribute to the teratogenicity of TCDD. However, in contrast to the low incidence of cleft palate observed in this study, others have reported no effect of TCDD on the incidence of cleft palate in another line of AhR-null mice (Mimura et al., 1997) . The difference between these results can not be determined from this work, but since both AhR mouse lines are not congenic, it is possible that genetic differences in either mouse model prevented characterization of a consistent phenotype. Additionally, one AhRnull mouse was constructed by effectively deleting the first exon of AhR by replacing it with a neomycin-resistance cassette (Fernandez-Salguero et al., 1995) , while the other AhRnull mouse was constructed by inserting a LacZ cassette into the first exon of AhR followed by a neomycin-resistance cassette (Mimura et al., 1997) . Whether this difference in gene targeting approach (Table 1) contributes to the difference in the incidence of cleft palate in the AhR-null fetuses exposed to TCDD remains unclear. Thus, while the data presented in this study suggest that AhR-independent mechanisms may contribute to the teratogenicity of TCDD, further research is needed to clarify this idea.
The higher percentage of resorptions observed in the (Ϫ/Ϫ) litters exposed to TCDD compared to TCDD-treated (ϩ/ϩ) litters is of great interest. This observation is consistent with another report that the total number of resorptions per total fetuses examined from AhR-null mice prenatally treated with TCDD is also higher compared to (ϩ/ϩ) mice treated with TCDD (Mimura et al., 1997) . However, these data are not presented as mean percentage of resorptions per litter and this difference was not discussed in this paper (Mimura et al., 1997) . Nonetheless, both reports suggest that mechanisms that do not require the AhR may contribute in part to this developmentally toxic effect of TCDD. Further, the trend of lower average fetal weight in (Ϫ/Ϫ) fetuses from TCDD-treated mice compared to controls suggests that this effect may also be the result of mechanisms that do not require the AhR. Indeed, it has been suggested that TCDD can cause increased lipid peroxidation and higher levels of fos and jun mRNA through mechanisms that may not require the AhR (Ashida et al., 1996; Hoffer et al., 1996; Puga et al., 1992) . Combined, these ob-servations suggest that the increase in the percentage of resorptions (and perhaps reduced fetal weight) may possibly be due to pathways that do not require the AhR. Since no difference in the percentage of resorptions was observed in (ϩ/ϩ) mice treated with TCDD, it is reasonable to suggest that in the absence of the AhR these effects are exacerbated or enhanced. These data support the idea that in the absence of AhR, there is a shift towards AhR-independent processes when there is no AhR available to bind TCDD. This shift in putative pathways could explain the difference in the percentage of resorptions between (ϩ/ϩ) and (Ϫ/Ϫ) mice treated with TCDD. The role(s) of putative AhR-independent pathways that contribute to TCDD-induced developmental toxicity remains unclear, but future work with the AhR-null mouse model should delineate the specific mechanisms underlying this effect. Finally, it will be of great interest to demonstrate that the effects described in this study are reproducible in congenic AhR-null mice to eliminate the possibility that the heterogeneity in the mixedbackground mouse line used in this work resulted in an ambiguous phenotype.
